Background: In malaria endemic regions, Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine (IPTp-SP) is recommended for all pregnant women during prenatal consultation from the fourth to the ninth month of pregnancy, up to the time of delivery. The Government of Mali is aiming for universal coverage of IPTp-SP. However, coverage is still low, estimated to be 18% for completion of three doses (IPTp-SP3). The objective of this study was to identify the factors that influence IPTp-SP in the Health District of Sélingué, Mali.Methods: We performed a cross-sectional survey with 30 clusters, proportional to village size with two stages of sampling. We collected data electronically with Magpi software during face-to-face interviews/surveys. The data were analyzed with SPSS version 20. We performed a descriptive analysis, and bivariate and multivariate logistic regression. An equity analysis examined the effect of distance from health care facility on completion of three or more antenatal visits (ANC3+) and three or more doses of Intermittent Preventive Treatment (IPTp-SP3+).Results: Of the 1,021 women surveyed, 87.8% (n = 896) attended at least one ANC visit. Of these, 86.3% (n = 773) received at least 1 dose of IPTp-SP. The frequency of three or more ANC visits was 90.8%. Compliance with three or more malaria treatments was 63.7%. The determinants statistically related to ANC3+ were the early initiation of ANC (OR = 3.22 [1.22, 10.78]), the number of payments made for the malaria treatment (OR = 21.5 [2.64; 09], OR = 11.24 [2.5, 50.46]) and the presence of a Community Health Center (CHC) in the village (OR = 9.69 [1.09, 86.21]). The ability to read (OR = 1.60 [1.01, 2.55]), the early initiation of ANC (OR = 1.46 [1.06, 2.00], knowledge of the utility of the drug (OR = 2.38 [1.24, 4.57]), and knowledge of the recommended dose of the drug (OR = 6.11 [3.98, 9.39]) were related to completion of three or more treatments (IPTp-SP3+).Conclusion: The early initiation of ANC was a good determinant of the completeness of ANC3+ and IPTp-SP3+. Coverage was fair, but still far from universal. Alternative strategies are needed to further increase coverage.